Currently, there are 120.51M common shares owned by the public and among those 109.84M shares have been available to trade.
The company’s stock has a 5-day price change of 0.76% and 0.16% over the past three months. RNA shares are trading 5.16% year to date (YTD), with the 12-month market performance up to 3.63% higher. It has a 12-month low price of $21.51 and touched a high of $56.00 over the same period. RNA has an average intraday trading volume of 1.53 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.43%, 3.69%, and -16.01% respectively.
Institutional ownership of Avidity Biosciences Inc (NASDAQ: RNA) shares accounts for 107.71% of the company’s 120.51M shares outstanding.
It has a market capitalization of $3.69B and a beta (3y monthly) value of 0.96. The earnings-per-share (ttm) stands at -$3.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.29% over the week and 5.84% over the month.
Earnings per share for the fiscal year are expected to decrease by -36.98%, and -11.64% over the next financial year. EPS should grow at an annualized rate of -1.71% over the next five years, compared to -34.37% over the past 5-year period.
Looking at the support for the RNA, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on March 13, 2025, with the firm’s price target at $70. BMO Capital Markets coverage for the Avidity Biosciences Inc (RNA) stock in a research note released on March 12, 2025 offered a Outperform rating with a price target of $72. Scotiabank was of a view on March 07, 2025 that the stock is Sector Outperform, while H.C. Wainwright gave the stock Buy rating on December 20, 2024, issuing a price target of $72. RBC Capital Mkts on their part issued Outperform rating on November 26, 2024.
